Innate Pharma Stock Momentum Indicators Average Directional Movement Index
| IPHA Stock | USD 1.54 0.04 2.67% |
| Symbol |
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The average directional index (ADX) measures the strength of a prevailing trend of Innate Pharma and whether movement exists in the market. The ADX is measured on a scale of 0 to 100. A low Innate Pharma ADX value usually indicates a non-trending market with low volumes, whereas a cross above 20 may indicate the start of a trend. If the ADX is over 40 and begins to fall, it can indicate the slowdown of a current trend. This indicator can also be used to identify non-trending markets, or a deterioration of an ongoing trend. Although market direction is important in its calculation, the ADX is not a directional indicator
Innate Pharma Technical Analysis Modules
Most technical analysis of Innate Pharma help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Innate from various momentum indicators to cycle indicators. When you analyze Innate charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Innate Pharma Predictive Technical Analysis
Predictive technical analysis modules help investors to analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Innate Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Innate Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Innate Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Innate Pharma's daily price indicators and compare them against related drivers, such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Innate Pharma's intrinsic value. In addition to deriving basic predictive indicators for Innate Pharma, we also check how macroeconomic factors affect Innate Pharma price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
| 2023 | 2024 (projected) | Dividend Yield | 0.002467 | 0.002344 | Price To Sales Ratio | 4.06 | 3.86 |
Be your own money manager
As an individual investor, you need to find a reliable way to track all your investment portfolios' performance accurately. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing you full analytical transparency into your positions, our tools can tell you how much better you can do without increasing your risk or reducing expected return.Generate Optimal Portfolios
Align your risk and return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innate Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.44) | Revenue Per Share 0.419 | Quarterly Revenue Growth (0.69) | Return On Assets (0.14) |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.